Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CCKAR | P32238 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TRPV4 | Q9HBA0 | 3/20 | 0.34 |
| ▸ | F10 | P00742 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 6/20 | 0.33 |
| ▸ | MPL | P40238 | 1/20 | 0.32 |
| ▸ | PLTP | P55058 | 2/20 | 0.32 |
| ▸ | ECE1 | P42892 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | POLQ | O75417 | 1/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6703653 | 0.90 | MEN1 (0.37) | MEN1CCKARKMT2ATRPV4F10 | |
| SCHEMBL7679752 | 0.89 | MEN1 (0.38) | MEN1CCKARKMT2ATRPV4MPL | |
| SCHEMBL7684176 | 0.89 | TRPV4 (0.38) | MEN1CCKARKMT2ATRPV4ECE1 | |
| SCHEMBL7688740 | 0.89 | MEN1 (0.46) | MEN1CCKARKMT2ATRPV4F10 | |
| SCHEMBL7688727 | 0.87 | TRPV4 (0.36) | MEN1CCKARKMT2ATRPV4PLTP | |
| SCHEMBL29403637 | 0.86 | TRPV4 (0.36) | MEN1CCKARKMT2ATRPV4PLTP | |
| SCHEMBL1008694 | 0.86 | TRPV4 (0.36) | MEN1CCKARKMT2ATRPV4PLTP | |
| SCHEMBL7688378 | 0.86 | MEN1 (0.38) | MEN1CCKARKMT2ATRPV4F10 | |
| SCHEMBL7688220 | 0.86 | TRPV4 (0.35) | MEN1CCKARKMT2ATRPV4PLTP | |
| SCHEMBL7688634 | 0.86 | MEN1 (0.37) | MEN1CCKARKMT2ATRPV4PLTP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080064715-A1 | 6-Azaindole Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-03-13 | — | — | US | claimed |
| US-7608627-B2 | I kappa B kinase inhibition; diabetes; (7-Chloro-1H-pyrrolo[2,3-c]pyridin-2-yl)methanol; N-Benzyl-7-chloro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-27 | — | — | US | disclosed |
| US-20080064715-A1 | 6-Azaindole Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064715-A1 | 6-Azaindole Compound | RELA, NFKBIA, GPR119 | MEN1 2705/4885CCKAR 203/4885KMT2A 1114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.